Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Shanghai Henlius BiotechHKSE:02696 -1.10%67 Days Payable is 137.26 as of Dec. 2025, which is 44% below its 10-year median of 245.03. GuruFocus rates HKSE:02696 with a GF Score™ of 67/100 and a GF Value™ of HK$30.91 (Significantly Overvalued). The stock has 4 warning signs investors should review. Among 703 Biotechnology companies, Shanghai Henlius Biotech ranks better than 59.6% on this metric.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
HKSE:02696 vs VRTX, REGN, RVMD: Days Payable Comparison
For the Biotechnology subindustry, Shanghai Henlius Biotech's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Shanghai Henlius Biotech Days Payable vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Shanghai Henlius Biotech's Days Payable distribution charts can be found below:
* The bar in red indicates where Shanghai Henlius Biotech's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Shanghai Henlius Biotech's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Shanghai Henlius Biotech (HKSE:02696) has a Days Payable of 137.26 as of Dec. 2025. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Shanghai Henlius Biotech and its competitors. This is 44% below median its historical median of 245.03. Over the past decade, Shanghai Henlius Biotech's Days Payable has ranged from 152.57 to 5,500.89. According to the industry distribution chart, Shanghai Henlius Biotech ranks #284 out of 703 companies in the Biotechnology industry, placing it in the top 40.4%.
Is Shanghai Henlius Biotech's Days Payable too high?
Shanghai Henlius Biotech's current Days Payable of 137.26 is 44% below median its 10-year median of 245.03. Over the past 10 years, this metric has ranged from a low of 152.57 to a high of 5,500.89. The Biotechnology industry median Days Payable is 112.39. Shanghai Henlius Biotech's value of 137.26 is 22.1% above this industry median. Based on the distribution chart, Shanghai Henlius Biotech ranks #284 out of 703 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Shanghai Henlius Biotech has a GF Score™ of 67/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Shanghai Henlius Biotech's Days Payable compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Shanghai Henlius Biotech ranks #284 out of 703 companies for Days Payable. This puts Shanghai Henlius Biotech in the upper half of its industry. The industry median Days Payable is 112.39. Shanghai Henlius Biotech's value of 137.26 is 22.1% above this benchmark. Historically, Shanghai Henlius Biotech's own Days Payable has ranged from 152.57 to 5,500.89 over the past decade. While the company's 10-year median is 245.03 vs. the industry median of 112.39, Shanghai Henlius Biotech has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Biotechnology company?
The median Days Payable among Biotechnology companies is 112.39, based on 703 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Shanghai Henlius Biotech's current Days Payable of 137.26 is 22.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Shanghai Henlius Biotech and its competitors. For the Biotechnology industry, the median Days Payable is 112.39 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Shanghai Henlius Biotech's current Days Payable is 137.26, which is 44% below median its own 10-year median of 245.03. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Shanghai Henlius Biotech stock overvalued right now?
Based on GuruFocus' analysis, Shanghai Henlius Biotech (HKSE:02696) is currently considered Significantly Overvalued. The stock's GF Value™ is HK$30.91, compared to a current price of HK$67.30 — trading 117.7% above its estimated fair value. The current Days Payable is 137.26, which is 44% below median its 10-year median of 245.03 and 22.1% above the Biotechnology industry median of 112.39. Shanghai Henlius Biotech's overall GF Score™ is 67/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Shanghai Henlius Biotech (HKSE:02696), the current Days Payable is 137.26 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Shanghai Henlius Biotech (HKSE:02696) Overvalued in 2026?
Based on GuruFocus' analysis, Shanghai Henlius Biotech stock appears to be overvalued.
The current stock price of HK$67.30 is trading 117.7% above its estimated GF Value™ of HK$30.91.
GuruFocus considers Shanghai Henlius Biotech to be Significantly Overvalued.
Key valuation signals for HKSE:02696:
Days Payable: 137.26 (44% below median its 10-year median of 245.03)
GF Value™: HK$30.91 vs. price of HK$67.30 (117.7% above fair value)
Industry Position: 22.1% above the Biotechnology median (#284 of 703)
No single metric tells the full story. See the HKSE:02696 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Shanghai Henlius Biotech Inc is a biopharmaceutical company in China with the vision to offer affordable and biologics for patients with a focus on oncology and autoimmune diseases. The Group is engaged in biopharmaceutical R&D, biopharmaceutical services, and biopharmaceutical production and sales. It operates in Mainland China, Asia Pacific (excluding Mainland China), North America, South America, Oceania, and Europe. The company products include HLX01 Rituximab, HLX02(trastuzumab), and others.
67GF Score
Get the complete analysis for HKSE:02696
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:02696 has been successfully added to your 
